FDA PCAC Meeting July 23–24: The Peptide Compounding Decision Point

On July 23–24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) convenes for what may be the most consequential peptide compounding meeting in recent history. While the GLP-1 crackdown gets headlines, this meeting could determine the regulatory future of an entire class of therapeutic peptides.

What PCAC Is — and Why It Matters

PCAC is an FDA advisory committee that provides expert input on drug substances nominated for inclusion on or removal from the lists governing what compounding pharmacies can produce. The committee includes pharmacists, physicians, toxicologists, and consumer representatives.

Their recommendations carry significant weight. While the FDA isn't bound by PCAC's votes, the committee's conclusions historically form the evidentiary basis for final regulatory decisions. A positive PCAC vote on a peptide's suitability for compounding is the strongest predictor of it being permitted.

The Agenda: What's Being Discussed

The meeting is expected to evaluate specific peptide candidates for potential inclusion on the 503B Bulks List or for guidance clarification regarding 503A compounding. Key topics will likely include:

• Safety review of nominated peptides — adverse event data, known risks, and quality concerns for commonly compounded peptides
• Clinical need assessment — whether there exists a clinical need for compounded versions of peptides that have no FDA-approved equivalent
• Quality standards — what testing, stability, and manufacturing requirements should apply to compounded peptide preparations
• Public comments — the committee will review submitted comments from practitioners, patients, and industry stakeholders

Why GLP-1 Patients Should Care

While GLP-1 peptides (semaglutide, tirzepatide) are not expected to be discussed for reclassification at this meeting, the outcome has indirect but meaningful implications for the broader compounding ecosystem that GLP-1 patients rely on:

If the PCAC recommends permitting compounding for a significant number of the 14 peptides under consideration, it validates the principle that compounding pharmacies serve a legitimate clinical function. This strengthens the legal and political position of 503A pharmacies — the same pharmacies that most compounded GLP-1 patients use.

Conversely, if the PCAC takes a restrictive position across the board, it could embolden further FDA enforcement actions against all forms of peptide compounding — including GLP-1s.

What to Watch For

The meeting is public. Watch for: individual peptide vote outcomes (particularly BPC-157 and thymosin alpha-1, which have the broadest clinical use), any discussion of a new regulatory framework for "compounding-eligible peptides" as a category, and signals about how the FDA views the relationship between peptide reclassification and the ongoing GLP-1 enforcement actions.

We'll publish a full analysis of the meeting outcomes within 48 hours of the session's conclusion. Follow our blog for the update.